This Article Abstract Full Text (PDF) All Versions of this Article: 37/5/1200    most recent 01.STR.0000217386.37107.bev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krupinski, J. Articles by Badimon, L. Search for Related Content PubMed PubMed Citation Articles by Krupinski, J. Articles by Badimon, L. Pubmed/NCBI databases Substance via MeSH Related Collections Angiogenesis Pathophysiology Gene expression Carotid Stenosis

(Stroke. 2006;37:1200.)
© 2006 American Heart Association, Inc.

Original Contributions

Endogenous Expression of C-Reactive Protein Is Increased in Active (Ulcerated Noncomplicated) Human Carotid Artery Plaques

Jerzy Krupinski, MD, PhD; Marta Miguel Turu, Msc; Jose Martinez-Gonzalez, PhD; Ana Carvajal, Msc; Josep Oriol Juan-Babot; Elena Iborra, MD; Mark Slevin, PhD; Francisco Rubio, MD Lina Badimon, PhD

From the Department of Neurology (J.K., M.M.T., A.C., F.R.), Stroke Unit, University Hospital of Bellvitge (HUB), and IDIBELL, Barcelona, Spain; Cardiovascular Research Centre (J.K., M.M.T, J.M.-G., J.O.J.-B., L.B.), IIBB/CSIC-HSCSP-UAB, Barcelona, Spain; the Department of Vascular Surgery (E.I.), University Hospital of Bellvitge (HUB), Barcelona, Spain; and the Department of Biological Sciences (M.S.), John Dalton Building, Manchester Metropolitan University, Manchester, UK.

Correspondence to Jerzy Krupinski, MD, PhD, Department of Neurology, Stroke Unit, Hospital Universitari de Bellvitge, Feixa Llarga s/n 08907 L’Hospitalet de Llobregat, Barcelona, Spain. E-mail krupinski{at}csub.scs.es

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Background and Purpose— There is growing evidence suggesting that C-reactive protein (CRP) is an effecter molecule able to induce and promote atherothrombosis. The presence of CRP in atherosclerotic plaques may reflect local production or infiltration from circulating CRP increased in general inflammatory responses. Our aim was to analyze the presence of CRP in human advanced carotid artery plaques with differential anatomo-pathological characteristics and to assess local expression of CRP and other proinflammatory genes in these lesions.

Methods— Human carotid artery specimens from 38 patients undergoing scheduled endarterectomy were classified into 3 groups: ulcerated (noncomplicated) (UNC, n=19), fibrous (F, n=12) and ulcerated (complicated/hemorrhagic) plaques (UC, n=7). The presence of CRP was evaluated by immunohistochemistry, and plasma samples were screened for circulating high-sensitivity C-reactive protein. TaqMan Low-density Arrays were used for study of genes related to inflammation (CRP, interleukin-6, macrophage colony-stimulating factor-1, monocyte chemotactic protein-1, cyclooxygenase-2).

Results— CRP mRNA levels were predominantly detected in UNC-high risk plaques but not in UC (P=0.001). UNC also exhibit the highest expression levels of other genes involved in the inflammatory responses: cyclooxygenase-2 (P<0.005 versus F and versus UC), IL-6 (P<0.005 versus F and versus UC) and monocyte chemoattractant protein-1 (P<0.01 versus F and versus UC). Plaque CRP mRNA levels correlated with immunohistochemical findings but were independent of plasma high-sensitivity CRP. In UNC plaques endothelial cells and inflammatory cells were strongly positive for CRP around areas of newly formed microvessels.

Conclusions— In human high-risk carotid artery plaques (UNC) CRP expression reflects an active proinflammatory stage. Local synthesis of CRP could be involved in plaque neovascularization and increased risk of hemorrhagic transformation.

Key Words: angiogenesis • carotid atherosclerosis • C-reactive protein

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Advanced atherosclerosis is thought to be a consequence of chronic local and systemic inflammatory disease. There are a large number of reports in favor of this hypothesis.¹ Chronic inflammation is directly related to altered coagulation and subsequently higher risk of symptomatic vascular disease.^2–3 C-reactive protein (CRP) is a powerful marker of future vascular events.^4,5 In addition, there is an association between intimal CRP deposition and the development of atherosclerotic plaque.⁶ In fact, recent evidence support a role for CRP as an effecter molecule able to induce proatherotrombotic phenotype in the vessel wall.⁷ CRP is a chemoattractant for monocytes,^8,9 upregulates adhesion molecules,¹⁰ and decreases NO release by endothelial cells,^6,11 induces plasminogen activator inhibitor type 1 expression¹² and tissue factor synthesis by vascular smooth-muscle cell (VSMC) and endothelial cells¹³ and exhibits both proliferative and apoptotic properties on vascular cells.^13,14 Finally, CRP increases matrix metalloproteinase-1 in monocytic cells in culture suggesting that it could promote matrix degradation and thus contribute to plaque vulnerability.¹⁵

Extra-hepatic synthesis of CRP has been reported in alveolar macrophages, neurons, lymphocytes, and in vascular cells.^16–19 In atherosclerotic lesions, immunohistochemical analysis demonstrated colocalization of CRP with VSMC and macrophages;^16,17 in these lesions CRP mRNA has been detected by real-time polymerase chain reaction (RT-PCR)¹⁷ and in situ hybridization in both VSMC and macrophages.¹⁶ CRP is mainly present in atherosclerotic lesions with active disease.¹⁷ In cell cultures CRP is produced by both VSMC and endothelial cells exposed to inflammatory cytokines¹⁸ or macrophage-conditioned medium.¹⁹ These data suggest that CRP present in atherosclerotic plaques may reflect local production rather than infiltration from circulating CRP produced by general inflammatory responses.

Although CRP seems to be a powerful proatherogenic and prothrombotic molecule, its possible effect on plaque complication and risk of subsequent vascular events has not been studied in detail. Identification of genes associated with vascular inflammatory biomarkers may provide new insights into local genetic determinants of vascular inflammation and risk of symptomatic vascular disease.^20–21 The aim of the present study was to examine the presence of CRP in human advanced carotid artery plaques and to assess local expression of CRP and other inflammatory genes in these lesions.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Patients and Blood Sample Collection
We included 38 patients undergoing carotid endarterectomy for symptomatic (transient ischemic attack, minor stroke) or asymptomatic stenosis >70% confirmed by MR angiography or conventional arteriography. Patients were screened for the presence of bilateral pathology (>50% contralateral stenosis) by EcoDoppler imaging. The presence of vascular risk factors was recorded and previous antihypertensive, statin and antiplatelet treatments were noted (Table 1). Patients’ anticoagulated were not included in the study. Plasma samples were collected after overnight fasting and immediately before endarterectomy; they were frozen in liquid nitrogen and stored at –80°C for further processing. There was no significant difference in time delay in the scheduled surgery. High-sensitivity C-reactive protein (hsCRP) was tested in EDTA-plasma samples by means of particle enhanced immunonephelometry using BN Systems (Dade Behring). For quantitative assay of hsCRP, patients with history of acute arterial or venous thromboembolism, active infections or inflammatory conditions, renal failure, hepatic disease, neoplasms, recent trauma or surgery were excluded. Patients with hsCRP values above 10 mg/L were retested. All other standard hematological and biochemistry analysis were routinely performed at the hospital laboratory. The study was approved by the local ethical committee in accordance with institutional guidelines.

View this table: [in this window] [in a new window]   TABLE 1. Patients Clinical Characteristics

Carotid Specimens/Histology/Immunohistochemistry
Carotid specimens were excised by the vascular surgeon without damage to the luminal surface. Additionally, carotid specimens from postmortem material (vascular transplants) were used as controls for mRNA and immunohistochemistry. They were immediately rinsed in 0.9% saline and cut longitudinally into 2 portions. One was snap frozen in liquid nitrogen and stored at –80°C and the other was fixed for 24 hours in buffered formalin and later cryoprotected in 30% sucrose and frozen in optimal cutting temperature for histology. Plaque morphology was assessed immediately after surgery and later by histology of hematoxylin and eosin-stained sections.²² Plaques were classified as ulcerated noncomplicated (UNC), ulcerated complicated (UC) that exhibited hemorrhagic transformation, or fibrous (F). For immunohistochemistry, 8 µm serial sections were cut with a cryostat. The peroxidase method was used for immunohistochemical staining (Vectastain kit; Vector). After blocking endogenous peroxidase, the sections were incubated with normal serum and then incubated at 4°C overnight with the primary monoclonal anti-CRP antibody (clone CRP-8; Sigma; 1:100). Afterward, sections were incubated for 1 hour with secondary antibody (1:200) at room temperature. The peroxidase reaction was visualized with 0.05% diaminobenzidine.²² Negative controls in which the primary antibody was replaced with PBS were used to test for nonspecific binding (data not included).

RNA Extraction and cDNA Synthesis
RNA was isolated from carotid plaques frozen immediately after surgery by using Tripure isolation Reagent (Roche Molecular Biochemicals) according to the manufacturer. Integrity and concentration of RNA was measured using a Bioanalyzer (Agilent) and then total RNA was converted to single stranded cDNA using High-Capacity cDNA Archive Kit according to the manufacturer (Applied Biosystems).

TaqMan Low-Density Array
The TaqMan Low-Density Array is a 96 TaqMan Gene Expression assay (Applied Biosystems) preconfigured in a 384-well format and spotted on a microfluidic card (2 replicates per assay).²³ Each TaqMan Gene expression Assay contains a forward and reverse primer for each of the chosen genes (ß-glucuronidase [GUS], CRP, interleukin-6 [IL-6], 18S ribosomal, macrophage colony-stimulating factor-1 [MCSF-1], monocyte chemotactic protein-1 [MCP-1] and cyclooxygenase-2 [COX-2]) at a final concentration of 900 nM and a TaqMan MGB probe (6-FAM dye-labeled; Applied Biosystems), 250 nM final concentration. GUS and 18S RNA were incorporated in our customized TaqMan Low-Density Array as internal standards. They were chosen among 11 candidate control genes previously checked using the TaqMan Human Endogenous Control Plate. Data were normalized using GUS because of the consistency of its level from sample to sample.

First, 50 µL of cDNA from each sample was combined with an equal volume of TaqMan Universal PCR Master Mix (Applied Biosystems), and was loaded into each of 8 ports on the TaqMan Low-Density Array cards. The real-time RT-PCR amplifications were run on an ABI Prism 7900Ht sequence Detection System (Applied Biosystems) with a TaqMan Low Density Array Upgarde. Thermal cycling conditions were as follows: 2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of denaturation at 95°C for 15 seconds, and annealing and extension at 60°C for 1 minute.

Statistical Analysis
Clinical, histological and The TaqMan Low-Density Array data were compared by using nonparametric statistics (based on the assumption that the data were not normally distributed), using Spearman rank test for paired samples, and Mann-Whitney U test for unpaired samples. The analyses were 2-tailed unless otherwise specified. For correlative analysis, the Spearman rank correlation coefficient (r) was calculated. Values were considered significant at P<0.05. Individual group values were expressed as mean±SD. The StatView statistical package was used for all analysis, and statistical evaluations were performed by a medical statistician.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Patient’s Baseline Characteristics
Patient’s demographic characteristics are presented in Table 1. Patients specimens were divided into 3 groups based on carotid plaque anatomo-pathological characteristics: UNC, F or UC. There was no significant difference in studied groups in gender, symptomatic carotid disease, individual or combined risk factors, treatment, or coexistence of other vascular disease. Patients with UNC had predominantly unilateral carotid pathology, ie, contralateral stenosis <50% as compared with others (P=0.02). There was no significant difference in basic biochemical parameters between studied groups (Table 2).

View this table: [in this window] [in a new window]   TABLE 2. Blood/Serum Parameters of Studied Subjects

Expression of Inflammatory Genes in Carotid Plaques
Table 3 summaries the results for The TaqMan Low-Density Array in carotid plaques. CRP mRNA was predominantly expressed in UNC but not in UC (P=0.001; Table 3). UC plaques were end-stage plaques with low cellular content and high necrotic component (see histology for details). CRP mRNA levels in fibrose plaques was much lower than in ulcerated (P=0.01; Table 3). The increased CRP expression in UNC plaques was not associated with any particular cardiovascular risk factor or treatment (Table 1). Further, blood/serum parameters, ie, leukocytes, fibrinogen, erythrocyte sedimentation rate, or cholesterol were comparable in all 3 groups (Table 2). CRP mRNA levels were independent of plasma hs-CRP (P=0.4; r=0.032). Thus, CRP mRNA levels were directly related to plaque ulceration representing the active state of the plaque at the time of the study (Table 3). Interestingly, ulcerated plaques had higher expression of other genes involved in inflammatory responses (COX-2, IL-6 and MCP-1) than the rest of the carotid plaques. No significant differences were observed in MCSF-1 expression.

View this table: [in this window] [in a new window]   TABLE 3. Inflammatory Genes in Carotid Plaques

Immunohistochemistry for CRP
Plaque CRP mRNA levels correlated with immunohistochemical findings. In the UNC plaques CRP immunostaining corresponded to areas of high cellular content with inflammatory cells (Figure, a). Furthermore, areas of newly formed microvessels were also strongly positive for CRP (Figure, b). UNC plaques had higher content of CRP-positive endothelial cells and inflammatory cells than other carotid plaques (Table 4). There was also notable immunostaining in VSMC within neointima (Figure, c). In the end-stage plaques with important intraplaque hemorrhage or necrosis (UC) staining was much weaker or absent. CRP immunostaining was weak or absent in control plaques, postmortem normal carotid artery and fibrous plaques.

View larger version (57K): [in this window] [in a new window]   Representative immunostaining for CRP in UNC carotid plaques. Positive CRP immunostaining corresponding to a VSMC-rich area (A), a neovessel-rich area (B) and an inflammatory cell-rich area (C). Upper panels (a through c): high-power views of areas labeled with an asterisk in A, B and C. Arrow heads indicate VSMC, endothelial cells and inflammatory cells positive for CRP in a, b and c respectively. Bar=100 µm.

View this table: [in this window] [in a new window]   TABLE 4. Immunostaining for CRP in Carotid Artery Plaques

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The main finding of this study was that ulcerated, potentially vulnerable carotid plaques, but not ulcerated-complicated carotid plaques are biochemically active plaques that over-express CRP and other inflammatory markers. In these plaques CRP was mainly located in neointimal areas enriched in inflammatory cells and microvessels. Furthermore, CRP expression level in these plaques was independent of cardiovascular risk factors, treatments, or plasma CRP levels. These findings seem to be important as so far all advanced carotid plaques in patients scheduled for endarterectomy have been considered as end-stage, and plaque progression measured by ultrasound usually estimates the grade of carotid stenosis rather than the exact stage of plaque activity.²⁰

CRP is frequently deposited in atherosclerotic lesions from human and animal models; however, its origin and the pathological significance of CRP in these lesions are not completely understood. In humans, there is little information on CRP expression in vascular tissues.^{16,17,24–26} CRP expression in the human vascular wall was first detected by Yasojima et al¹⁶ in the thickened intima of middle aortic lesions colocalizing with VSMC and macrophages. Recent studies have found CRP mRNA in coronary arteries,²⁴ femoral,²⁵ and carotid plaques.²⁶ Jabs et al¹⁷ reported that CRP was expressed in active sites of middle coronary atherosclerotic lesions (type IV and V), but not in end-stage plaques, and identified VSMC as the predominant cell type expressing CRP. Recently Sattler et al²⁶ described important expression levels of inflammatory markers, including nuclear factor B and CRP, in cell-rich areas from carotid endarterectomy specimens, especially in plaque shoulder and microvessels. However, it is not clear from the literature whether in situ expressed inflammatory markers differ in anatomo-pathological distinct carotid plaques.

We show that not all of the end-stage carotid plaques undergoing scheduled endarterectomy are biochemically equal. In fact, we identified a subgroup of "active" plaques (Ulcerated, UNC) that exhibit the highest levels of expression of CRP and other inflammatory markers (IL-6, COX-2 and MCP-1). In these plaques CRP was mainly located in cell-rich areas, VSMC, newly formed blood vessels and inflammatory cells, in agreement with results published by Sattler et al.²⁶ Taken into account that IL-6 is the main inducer of CRP^18,19 and that CRP mediates MCP-1 expression in endothelial cells and monocytes^10,27 and increases monocyte response to MCP-1,⁸ the concomitant upregulation of CRP, IL-6, and MCP-1 could reflect a self-maintained proinflammatory mechanism in these active plaques. In addition, CRP could contribute to plaque destabilization; it has been suggested by previous studies that CRP increased matrix metalloproteinase-1 production by monocytic cells.¹⁵ The expression of CRP in carotid UNC plaques was associated with histological features of vulnerable plaque (enriched in inflammatory cells), suggesting that it might play a role in plaque instability. This is in agreement with findings of demonstrating an association of CRP expression in coronary plaques with histological features of vulnerable plaque.²³

Furthermore, CRP may be not only linked to vascular inflammation⁹ but also to intraplaque angiogenesis. It has been shown that CRP induces VSMC and endothelial cell proliferation.¹³ Therefore, CRP produced by vascular resident (VSMC endothelial cells) and infiltrated cells (monocytes and lymphocytes) in active carotid plaques could contribute to the increase in the number of neovessels observed in these lesions, and it could be associated with an increased risk of intraplaque hemorrhage.

Circulating CRP is a powerful, independent biomarker of vascular events.³ At least in part, it may originate from the atherosclerotic plaque. Indeed, there is some recent evidence that walls of pathological vessels secrete proteins that could be markers for atherosclerosis.^28,29 Inoue et al³⁰ suggested that local release of CRP protein from vulnerable plaque or coronary arterial wall injured by stenting, could be a marker for plaque instability or poststent inflammatory status. We further support the concept that atherosclerosis development and progression may be related to local synthesis of CRP.⁶ Although in our study no correlation was found between local and circulating CRP, we suggest that local CRP expression of atherosclerotic lesions might contribute to the distinct serum CRP elevations that are seen in atherosclerosis and correlate with the extent of the disease.¹⁷

Sattler et al²⁶ found that combined treatment with renin-angiotensin system blockers and ASA (COX-2 pathway blocking agents) decreased the expression of inflammatory markers in carotid arterial plaques. In our study, all patients were on antiplatelets and there was no difference in treatment with renin-angiotensin system blockers (angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists) in each group. However, these treatment modalities did not alter inflammatory marker expressed and relation to the anatomo-pathological state of the plaque.

In summary, the role of CRP in atherosclerotic lesions may go beyond inflammatory modulation, and we hypothesize that it could be a key player regulating lesion development and remodeling and triggering plaque rupture. Recent studies concluded that elevated hsCRP is an indirect risk factor for ischemic stroke based on its expression during the development of carotid atherosclerosis.³¹ In this study local CRP mRNA did not correlate with circulating hsCRP; however, expression was associated with vulnerable atherosclerotic lesion. To our knowledge this is the first study showing that intraplaque CRP could be regarded as a biomarker of a particular subgroup of "active" end-stage carotid plaques. Although measurement of intraplaque CRP could be important in the identification of vulnerable patients, currently available techniques do not permit for easy in situ CRP determination. Follow-up studies are required to confirm that local inflammatory responses and plaque hemorrhagic transformation are followed by vascular complications in these patients. However, such an intense local inflammatory response in advanced, ulcerated noncomplicated plaques suggests that these patients should be screened with new imaging techniques before the development of symptomatic disease.

	Acknowledgments

 
This work was supported by the following grants: Marie Curie Reintegration grant (ERG-011511) to J.K.; Proyecto Ictus, Spain; Plan Nacional de Salud SAF 2003–03187, FIS PI020361, PI020392 and FIS-C03/01.

	Footnotes

 
*First 3 authors contributed equally to this article.

Received December 13, 2005; revision received January 18, 2006; accepted February 2, 2006.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Ridker PM. C-reactive protein in 2005. Interview by Peter C. Block. J Am Coll Cardiol. 2005; 46: CS2–CS5.[Medline] [Order article via Infotrieve]

2. Retterstol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction: a 10 year follow-up study. Atherosclerosis. 2002; 160: 433–440.[CrossRef][Medline] [Order article via Infotrieve]

3. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.[Abstract/Free Full Text]

4. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]

5. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet. 2001; 358: 946–948.[CrossRef][Medline] [Order article via Infotrieve]

6. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998; 18: 1386–1392.[Abstract/Free Full Text]

7. Paul A, Yeh ET, Chan L. A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol. 2005; 16: 512–517.[Medline] [Order article via Infotrieve]

8. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ, Hong MK, Park SW, Park SJ. C-reactive protein promotes monocyte chemoattractant protein-1–mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation. 2004; 109: 2566–2571.[Abstract/Free Full Text]

9. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20: 2094–2099.[Abstract/Free Full Text]

10. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001; 103: 2531–2534.[Abstract/Free Full Text]

11. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106: 913–919.[Abstract/Free Full Text]

12. Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N, Kongo M, Kato S, Yamada N, Isaka N, Nakano T. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2005; 25: 2088–2093.[Abstract/Free Full Text]

13. Cirillo P, Golino P, Calabro P, Cali G, Ragni M, De Rosa S, Cimmino G, Pacileo M, De Palma R, Forte L, Gargiulo A, Corigliano FG, Angri V, Spagnuolo R, Nitsch L, Chiariello M. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res. 2005; 68: 47–55.[Abstract/Free Full Text]

14. Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, Okura T, Higaki J, Graf K, Fleck E, Hsueh WA, Law RE. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation. 2004; 110: 579–587.[Abstract/Free Full Text]

15. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcRII and extracellular signal-regulated kinase pathway:: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 2004; 24: 61–66.[Abstract/Free Full Text]

16. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039–1051.[Abstract/Free Full Text]

17. Jabs WJ, Theissing E, Nitschke M, Bechtel JF, Duchrow M, Mohamed S, Jahrbeck B, Sievers HH, Steinhoff J, Bartels C. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation. 2003; 108: 1428–1431.[Abstract/Free Full Text]

18. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003; 108: 1930–1932.[Abstract/Free Full Text]

19. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005; 166: 1265–1271.[Abstract/Free Full Text]

20. Rubio F, Martinez-Yelamos S, Cardona P, Krupinski J. Carotid endarterectomy: is it still a gold Standard? Cerebrovasc Dis. 2005; 20: 119–122.[Medline] [Order article via Infotrieve]

21. Martinez-Gonzalez J, Berrozpe M, Varela O, Badimon L. Heterogeneity of smooth muscle cells in advanced human atherosclerotic plaques: intimal smooth muscle cells expressing a fibroblast surface protein are highly activated by platelet-released products. Eur J Clin Invest. 2001; 31: 939–949.[CrossRef][Medline] [Order article via Infotrieve]

22. Slevin M, Baset Elasubi A, Miguel Turu M, Krupinski J, Badimon L, Gaffney J. Identification of differential protein expression associated with development of unstable human carotid plaques. Am J Pathol. 2006; 168: 1004–1021.[Abstract/Free Full Text]

23. Abruzzo LV, Lee KY, Fuller A, Silverman A, Keating MJ, Medeiros LJ, Coombes KR. Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. Biotechniques. 2005; 38: 785–792.[Medline] [Order article via Infotrieve]

24. Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, Fujita H, Awano K, Kobayashi K, Azumi H, Ejiri J, Hirata K, Kawashima S, Hayashi Y, Yokozaki H, Itoh H, Yokoyama M. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol. 2003; 23: 1398–1404.[Abstract/Free Full Text]

25. Vainas T, Stassen FR, de Graaf R, Twiss EL, Herngreen SB, Welten RJ, van den Akker LH, van Dieijen-Visser MP, Bruggeman CA, Kitslaar PJ. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005; 42: 243–251.[CrossRef][Medline] [Order article via Infotrieve]

26. Sattler KJ, Woodrum JE, Galili O, Olson M, Samee S, Meyer FB, Zhu XY, Lerman LO, Lerman A. Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques. Stroke. 2005; 36: 14–20.[Abstract/Free Full Text]

27. Zhou P, Thomassen MJ, Pettay J, Deodhar SD, Barna BP. Human monocytes produce monocyte chemoattractant protein 1 (MCP-1) in response to a synthetic peptide derived from C-reactive protein. Clin Immunol Immunopathol. 1995; 74: 84–88.[CrossRef][Medline] [Order article via Infotrieve]

28. Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, Jensen ON, Hernandez-Merida S, Tunon J, Vivanco F, Egido J. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004; 110: 2216–2219.[Abstract/Free Full Text]

29. Miguel Turu M, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, Alvarez-Sabin J, Cairols M, Badimon L. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2005; 27 OCT (in press).

30. Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, Imoto Y, Saito M, Hashimoto S, Hikichi Y, Node K. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol. 2005; 46: 239–245.[Abstract/Free Full Text]

31. Benbir G, Bozluolcay M, Ince B. Is the level of C-reactive protein correlated with the extent of carotid atherosclerosis? Acta Neurol Belg. 2005; 105: 73–80.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				B. Molins, E. Pena, G. Vilahur, C. Mendieta, M. Slevin, and L. Badimon C-Reactive Protein Isoforms Differ in Their Effects on Thrombus Growth Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2239 - 2246. [Abstract] [Full Text] [PDF]

				F. Montecucco, S. Steffens, F. Burger, G. Pelli, C. Monaco, and F. Mach C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes J. Leukoc. Biol., October 1, 2008; 84(4): 1109 - 1119. [Abstract] [Full Text] [PDF]

				D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent Am. J. Pathol., January 1, 2008; 172(1): 22 - 30. [Abstract] [Full Text] [PDF]

				M. Boehme, F. Kaehne, A. Kuehne, W. Bernhardt, M. Schroder, W. Pommer, C. Fischer, H. Becker, C. Muller, and R. Schindler Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2224 - 2229. [Abstract] [Full Text] [PDF]

				P. Gao, Z.-q. Chen, Y.-h. Bao, L.-q. Jiao, and F. Ling Correlation Between Carotid Intraplaque Hemorrhage and Clinical Symptoms: Systematic Review of Observational Studies Stroke, August 1, 2007; 38(8): 2382 - 2390. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 37/5/1200    most recent 01.STR.0000217386.37107.bev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krupinski, J. Articles by Badimon, L. Search for Related Content PubMed PubMed Citation Articles by Krupinski, J. Articles by Badimon, L. Pubmed/NCBI databases Substance via MeSH Related Collections Angiogenesis Pathophysiology Gene expression Carotid Stenosis